European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Businesswire·2026-04-02 18:45

公司动态 - 默克公司的KEYTRUDA®（帕博利珠单抗）联合紫杉醇，加或不加贝伐珠单抗，获得欧盟批准用于治疗铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌成年患者 [1] - 该批准针对肿瘤表达PD-L1且综合阳性评分≥1，并已接受过一或两种前期全身治疗方案的患者 [1] 产品与市场 - KEYTRUDA®在欧盟获得新适应症批准，将用于妇科肿瘤领域 [1]

CPS Technologies-European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens - Reportify